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Slit is a large secreted protein that provides important guid-
ance cues in the developing nervous system and in other organs.
Signaling by Slit requires two receptors, Robo transmembrane
proteins and heparan sulfate (HS) proteoglycans. How HS con-
trols Slit-Robo signaling is unclear. Here we show that the sec-
ond leucine-rich repeat domain (D2) of Slit, which mediates
binding to Robo receptors, also contains a functionally impor-
tant binding site for heparin, a highly sulfated variant of HS.
Heparin markedly enhances the affinity of the Slit-Robo inter-
action in a solid-phase binding assay. Analytical gel filtration
chromatography demonstrates that SlitD2 associateswith a sol-
uble Robo fragment and a heparin-derived oligosaccharide to
form a ternary complex. Retinal growth cone collapse triggered
by Slit D2 requires cell surface HS or exogenously added hepa-
rin. Mutation of conserved basic residues in the C-terminal cap
region of Slit D2 reduces heparin binding and abolishes biolog-
ical activity.We conclude that heparin/HS is an integral compo-
nent of the minimal Slit-Robo signaling complex and serves to
stabilize the relatively weak Slit-Robo interaction.
Slits are large secreted leucine-rich repeat (LRR)6 proteins
with multiple roles in cell signaling and adhesion. They have
well established and evolutionarily conserved functions as
guidance cues in the developing nervous system (1, 2), but Slits
are also important in the development of the vasculature (3)
and other organs (4). The first class of Slit receptors to be iden-
tified were Robo family members, which are transmembrane
proteins with an extracellular domain resembling cell adhesion
molecules and a large cytosolic signaling domain (1, 2). Bio-
chemical studies have defined the domains mediating the Slit-
Robo interaction (5, 6), aswell as someof the components of the
signaling cascade downstream of Robo activation (7, 8), but
how binding of Slit to Robo receptors conveys a signal across
the cell membrane remains unknown.
The first indication that theremight exist a second Slit recep-
tor came from the observation that heparan sulfate (HS) was
required for the repellent activity of Slit in vitro (9) and in vivo
(10). The identity of this receptorwas revealed by recent genetic
studies in invertebrates, which showed that Slit signaling
requires Robo to be co-expressed on the same cell with the HS
proteoglycan syndecan (11–13). Syndecan is a membrane-
spanning protein to which are covalently attached several HS
chains, consisting of repeating sulfated disaccharide units
(14). Heparin is a member of the HS family that is more
highly and uniformly sulfated than other HS. Johnson et al.
(12) showed that both Slit and Robo can be co-immunopre-
cipitated with syndecan, suggesting the presence of a ternary
(or higher order) complex at the neuronal cell membrane.
However, the composition and functional relevance of this
putative ternary complex was not established. Because the
Slit distribution was found to be altered in syndecan-defi-
cient embryos, HS may also be required for Slit localization
rather than signaling (12).
Here we provide direct biochemical and functional evidence
for a ternary signaling complex composed of the second LRR
domain of Slit, Robo, and heparin/HS. Other Slit domains are
dispensable for signaling in an in vitro growth cone collapse
assay, but heparin/HS is required absolutely. We conclude that
heparin/HS is an integral component of the minimal Slit-Robo
signaling complex.
EXPERIMENTAL PROCEDURES
ExpressionVectors—All constructsweremade byPCRampli-
fication from complete cDNA clones, kindly provided by Dr.
Guy Tear (King’s College, London, UK) and Dr. Lindsay Hinck
(University of California, Santa Cruz). Primer sequences are
available upon request. The PCR products were cloned into
modified pCEP-Pu vectors, coding for proteins with a His tag
either at the N terminus (Slit constructs) or at the C terminus
(Robo constructs). A Robo IG1–5 Fc construct was made by
replacing the C-terminal His tag with a human Fc sequence
obtained by PCR amplification from the pFUSE-hFc1 vector
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(InvivoGen). Mutations in human Slit2 (hSlit2) D2 were intro-
duced by strand overlap extension PCR. The insert sequences
of all expression vectors were verified by DNA sequencing. The
domain boundaries of the Slit LRR domains and the RoboD1–5
construct have beendescribedpreviously (5). Thenewconstructs
have the following boundaries (sequence numbering includes
the signal peptide): Slit EG1-5, NACFE . . . YPQTS (933–1137);
Slit EG6-LG-EG7, QTSPC . . . TVTAA (1134–1430); Slit CT,
QGEGS . . . TKKCY (1417–1504); Slit EG6-LG-EG7-CT,
QTSPC . . . TKKCY (1134–1504); hSlit2 D2, SVLHC . . . FADLA
(269–505); RoboD1-2,GQYQS . . . IVQVK (51–254); RoboD3-5,
KPYFM . . . AADPS (254–546). The following vector-derived
sequences are additionally present in the mature proteins:
APLVHHHHHHALA and APLA, respectively, at the N terminus
of all Slit and Robo constructs; AAAHHHHHHat the C terminus
of His-tagged Robo constructs; andAAAVECPP . . . SLSPG at the
C terminus of the Robo IG1–5 Fc construct.
Protein Production—All proteinswere purified from the con-
ditioned medium of episomally transfected 293-EBNA cells as
described (5). Briefly, cells weremaintained inDulbecco’smod-
ified Eagle’s medium, 10% fetal calf serum (Invitrogen), trans-
fected using FuGENE reagent (Roche Applied Science), and
selected with 1 g/ml puromycin (Sigma). His-tagged proteins
were purified from serum-free conditioned medium using
TALON affinity beads (BD Biosciences) or 5-ml HisTrap col-
umns (GE Healthcare). The EG6-LG-EG7-CT construct was
additionally purified by preparative heparin affinity chroma-
tography. The Robo IG1–5 Fc protein was purified using pro-
tein A-Sepharose resin (Sigma). Purified proteins were dialyzed
into TBS, analyzed by SDS-PAGE, and quantified bymeasuring
their absorption at 280 nm.
Oligosaccharide Production—Defined heparin-derived oli-
gosaccharides were prepared as described (15, 16). Briefly,
bovine lung heparin (Calbiochem) was partially digested using
heparinase I (IBEX Technologies, Inc.). Partial digests were
fractionated by gel filtration chromatography on a Superdex 30
preparation grade column (3  200 cm) run at 0.5 ml/min in
0.5 M ammonium hydrogen carbonate. Size-defined fractions
were further separated by strong anion exchange chromatogra-
phy using a Propac PA1 column (0.9 25 cm; Dionex), eluting
with a linearNaCl gradient (0–1M). Pooled peak fractions were
desalted and lyophilized. Purified oligosaccharides were ana-
lyzed by PAGE and quantified by weighing or by measuring
their absorption at 232 nm.
Solid-phase Protein Binding Assay—The solid-phase binding
assay was carried out as described (5). Briefly, Slit D1-4 (100
g/ml) was coated onto 96-well microtiter plates (NUNC
Maxisorp).Wells were blocked with TBS/casein/Tween 20 and
washed with TBS. Robo IG1–5 Fc protein was added for 1 h.
After four washes, bound protein was detected by alkaline
phosphatase-conjugated goat anti-human Fc antibody (Sigma).
In some experiments, heparin (Sigma, 10 g/ml) was added
together with Robo IG1–5 Fc.
Chromatography—All chromatography experiments were
done on an A¨kta system (GE Healthcare). A 5-ml heparin
HiTrap column equilibrated in 50 mM Tris-HCl, pH 7.5, was
used to determine heparin affinities; bound proteins were
eluted with a linear NaCl gradient (0–2 M for the EG6-LG-
EG7-CT construct and 0–1 M for all other constructs). Gel fil-
tration chromatography was carried out using a 24-ml Super-
dex 75 column run at 0.5 ml/min in 20 mM Na-HEPES, pH 7.5,
150 mM NaCl.
Growth Cone Collapse Assay—The retinal growth cone col-
lapse assaywas performed as described (8). Briefly,Xenopus eye
primordia were dissected from stage 35/36 embryos and cul-
tured at 20 °C on coverslips coated with 10 g/ml poly-L-lysine
(Sigma) and 10 g/ml laminin (Sigma) for 24 h. hSlit2 D2 pro-
teins (40 nM), hSlit2 conditioned medium (positive control), or
TBS (negative control) were added directly to cultured explants
for 10 min. Cultures were then fixed for 1 h in 2% paraformal-
dehyde 7.5% sucrose and then mounted. The number of col-
lapsed growth cones was counted in blind conditions. Heparin
or HS (Sigma; 100 g/ml) was added immediately prior to the
addition of hSlit2 D2. For cultures treated with heparinase 1
(Sigma; 2.5 units/ml), the enzyme was added 3 h before the
addition of hSlit2 D2. Each experiment was conducted inde-
pendently a minimum of four times.
RESULTS
Mapping of Heparin-binding Sites in Slit and Robo—To
locate the heparin-binding site(s) within the large Drosophila
Slit protein, we used a panel of recombinant proteins spanning
the entire molecule. In a previous study we had shown that the
LRR region of Slit consists of four distinct domains, D1–4, each
comprising an array of LRRs flanked by cysteine-rich caps, and
we mapped the Robo-binding site to a highly conserved region
on the concave face of SlitD2 (5). In addition to the LRRdomain
constructs available from that study, we prepared several new
constructs spanning the C-terminal portion of Slit (Fig. 1). The
EG1-5 construct contains the five epidermal growth factor-like
domains following the LRR region and terminates at a natural
proteolytic cleavage site of Slit (1). The EG6-LG-EG7-CT con-
struct contains the remainder of the Slit C-terminal region; a
truncated version of this construct, EG6-LG-EG7, was used to
assess the contribution to heparin binding of the C-terminal
(CT) cystine knot domain. It was not possible to study heparin
binding by the CT domain directly, as the isolated CT domain
was not secreted by 293 cells transfected with the relevant
expression vector.
The recombinant Slit proteins were analyzed by heparin
affinity chromatography. Several proteins did not bind to the
heparin column; those that did eluted in single sharp peaks, and
the NaCl concentration required for elution was taken as a
measure of relative heparin affinity. We found that heparin-
binding sites are located at either end of the Slit protein,
whereas the central portion does not interact with heparin (Fig.
1A). These findings are in agreement with an earlier study on
the two natural cleavage products of hSlit2 (17). The CT
domain of Drosophila Slit has the highest apparent affinity for
heparin (compare EG6-LG-EG7-CT and EG6-LG-EG7), but
the N-terminal LRR domains of Slit, D1 and D2, also bind to
heparin, and their combined presence in D1–4 results in a sub-
stantial affinity for heparin.
We also tested whether the Slit-binding ectodomain of Dro-
sophila Robo displays affinity for heparin. Robo IG1–5 bound
quite strongly to the heparin affinity column; further dissection
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of this region into IG1–2 and IG3–5 showed that the heparin
binding activity is fully contained within IG1–2 (Fig. 1A).
Formation of a Ternary Slit-Robo-Heparin Complex—The
experiments described above demonstrate that both the Robo-
binding domain of Slit (D2) (5) and the Slit-binding region of
Robo (IG1–2) (6) bind heparin, raising the intriguing possibility
of a ternary Slit-Robo-heparin complex. To see whether hepa-
rin had an effect on the Slit-Robo interaction, we first carried
out a solid-phase binding experi-
ment (Fig. 2) in the absence and
presence of soluble heparin. Addi-
tion of 10 g/ml heparin resulted in
a marked (greater than 10-fold)
increase of the apparent affinity of
Robo D1–5 Fc for Slit D1–4. Thus,
heparin enhances the Slit-Robo
interaction, most likely via the for-
mation of a ternary Slit-Robo-hepa-
rin complex.
To obtain direct evidence for ter-
nary complex formation, we used
analytical gel filtration chromatog-
raphy (Fig. 3A). Drosophila Slit D2
(27.4 kDa  two N-linked glycans)
behaved as a monomer, as reported
previously (5). The elution volume
of Drosophila Robo IG1–2 (24.1
kDa) is also most compatible with a
monomer, considering that this
construct is likely to adopt an
extended conformation and will
therefore elute earlier than a globu-
lar protein of the same mass. When
Slit D2 and Robo IG1–2 weremixed
in a 1:1 ratio, a single peak was
observed that eluted ahead of the individual proteins, demon-
strating formation of a binary complex. SDS-PAGE showed
that the peak fractions contained Slit D2 and Robo IG1–2 in
comparable amounts (Fig. 3B). The Slit D2-Robo IG1–2 com-
plex must have 1:1 stoichiometry, given that its elution volume
of 10.9 ml corresponds to an 55-kDa globular protein. The
close correspondence to the calculated mass (51.5 kDa 
twoN-linked glycans) indicates a compact shape of the com-
plex. The shoulder at a higher elution volume may result
from partial dissociation of the complex on the column.
We next tested whether addition of heparin to the minimal
Slit-Robo complex results in the formation of a ternary com-
plex. Because native heparin is too large and polydisperse to be
used in these experiments, we used a purified heparin-derived
decasaccharide composed of repeating trisulfated disaccharide
units, which was expected to be long enough to span the mini-
mal Slit-Robo complex. When Slit D2, Robo IG1–2, and the
heparin decasaccharide were mixed in a 1:1:1 ratio, the result-
ing complex eluted even earlier than the binary Slit-Robo com-
plex, indicating formation of a ternary Slit-Robo-heparin com-
plex (Fig. 3A). SDS-PAGE of the peak fractions again
demonstrated the presence of Slit and Robo in comparable
amounts (Fig. 3B). Given that a heparin decasaccharide has a
similar hydrodynamic radius as an 20-kDa globular protein
(18) and that the elution volume of the ternary complex corre-
sponds to an 70-kDa globular entity, the most likely stoichi-
ometry of the ternary Slit-Robo-heparin complex is 1:1:1. Inter-
estingly, when the heparin decasaccharide was added to the
individual Slit D2 and Robo IG1–2 proteins, no interaction was
detected by gel filtration chromatography (data not shown),
FIGURE 1.Heparin-binding sites in Slit and Robo. A, domain structure and heparin binding ofDrosophila Slit
and Robo constructs (D1–4, leucine-rich repeat domains; EG, epidermal growth factor-like domain; LG, laminin
G-like domain;CT, C-terminal domain; IG, IG-like domain). Affinities for heparin are expressed as themolar NaCl
concentration required for elution from a heparin HiTrap column (nb, no binding at physiological ionic
strength). Full-length Slit and Robo are shown for reference; the domains responsible for their interaction (5, 6)
are shaded gray, and the transmembrane segment of Robo is represented by a vertical bar. B, Coomassie
Blue-stained SDS-polyacrylamide gel of selected Slit constructs. The molecular masses (in kDa) of selected
markers are indicated on the left.
FIGURE 2. Heparin enhances the Slit-Robo interaction. Binding of soluble
Robo IG1–5 Fc to immobilized Slit D1–4 in the absence and presence of 10
g/ml heparin. Bound Robo IG1–5 Fc was detected by alkaline phosphatase-
conjugated anti-Fc antibody. 1 g/ml Robo D1–5 Fc corresponds to 25 nM
Robo monomer. Values are presented as mean S.E. (n 3).
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suggesting that a high affinity binding site is only formed in the
Slit-Robo complex.
Heparin-dependent Biological Activity of Slit D2—Our bio-
chemical observation of a minimal Slit-Robo-heparin complex
suggests that an important function of heparin/HS in Slit-Robo
signaling may be to strengthen the association of Slit domain
D2 with Robo receptors. If this is indeed the case, one would
expect Slit D2 to display a similar heparin/HS-dependent
activity as full-length Slit, even though it is lacking the C-ter-
minal high affinity heparin-binding site of the full-length
molecule. In a previous study, we used an endothelial cell
migration assay to demonstrate biological activity of Slit D2
(5). A drawback of this assay is that endothelial cells express
a divergent member of the Robo family, Robo4, whose role as
a Slit receptor is controversial (19–21). In the absence of
further studies, it is therefore difficult to attribute the effect
of Slit on endothelial cells to a specific Robo receptor. More-
over, all studies into the HS requirement of Slit-Robo signal-
ing so far have focused on (cells of) the nervous system
(9–13, 22–24). To facilitate comparison with these studies,
we therefore decided to use a chemotropic collapse assay on
cultured Xenopus retinal growth cones.
In this assay, conditioned medium of cells expressing
hSlit2 induces growth cone collapse in a Robo- and heparin/
HS-dependent manner (8). We found that recombinant
hSlit2 D2 protein (61.5 and 96.6% sequence identity to Dro-
sophila and Xenopus Slit D2, respectively) applied at 40 nM
(the optimal concentration determined in a dose-response
experiment; data not shown) elicited a robust collapse
response, comparable with that obtained with hSlit2 condi-
tioned medium (Fig. 4, A–C and H). As expected from our
previous analysis (5), other Slit domains were inactive (data
not shown). Addition of heparin or HS had no effect on the
collapse-inducing activity of hSlit2 D2 (Fig. 4,D, E, andH). In
sharp contrast, enzymatic removal of HS from the neurites
by heparinase treatment abolished the response to hSlit2 D2,
demonstrating that Slit-Robo signaling does not occur in the
absence of HS chains at the cell surface. Remarkably, addi-
tion of heparin to heparinase-digested growth cones fully
restored their sensitivity to hSlit2 D2 (Fig. 4, G and H), indi-
cating that, in this assay format, exogenous soluble hepa-
rin/HS can substitute for endogenous HS proteoglycans to
support productive signaling. Taken together, the results
demonstrate that the D2 domain of Slit contains not only the
unique Robo-binding site but also a functionally important
heparin/HS-binding site.
Location of the Heparin/HS-binding Site in Slit D2—Wenext
wanted to determine which residues in Slit D2 contribute to
heparin/HS binding. Because the role of HS in Slit-Robo signal-
ing appears to be conserved between invertebrates and verte-
brates (9–13, 22, 23), we looked for conserved basic residues
FIGURE 3. Gel filtration analysis of a minimal ternary Slit-Robo-heparin
complex. A, gel filtration chromatograms of isolated Drosophila Slit D2 and
Robo IG1–2, a 1:1 mixture of the two proteins, and a 1:1:1 mixture of the two
proteinswith a heparin-deriveddecasaccharide (hep10). The elution volumes
of two globular molecular mass standards are indicated by vertical arrows
(albumin, 66 kDa; carbonic anhydrase, 29 kDa). The void volume of the col-
umn is 8.0 ml. The fractions collected for SDS-PAGE analysis are indicated.
B, Coomassie Blue-stained SDS-PAGE gel of the peak fractions indicated in A.
The fraction numbers are shown at the top.
FIGURE 4. Heparin/HS-dependent collapse of Xenopus retinal growth cones by hSlit2 D2. Growth cones were treated with TBS buffer control (A), condi-
tionedmediumof hSlit2-expressing cells (B), and 40 nM of purified hSlit2 D2 (D--G). Heparin (D andG) or HS (E) was added at a concentration of 100g/ml, and
in some experiments (F and G) growth cones were pretreated with heparinase 1 (2.5 units/ml). H, quantification of the collapse data shown in A–G. Values are
presented as percentage of growth cone collapse S.E. *, p 0.03, two-tailed Mann-Whitney U test. Scale bar, 5 m.
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thatmight be involved inHSbinding. Becausewewanted to test
the mutants in the growth cone collapse assay, we chose hSlit2
D2 for mutagenesis. Using an alignment of invertebrate and
vertebrate Slit sequences (Fig. 5A) and a molecular model of
hSlit2 D2 (Fig. 5B), we selected a total of 12 basic residues for
mutagenesis (Table 1). Mutants
1–4 target a basic patch in the
N-terminal region of hSlit2 D2, and
mutants 5–7 target a large concen-
tration of basic charges in the C-ter-
minal cap of the D2 domain (Fig.
5B). Both of these basic patches are
adjacent to the Robo-binding site
defined in our previous study (5).
All hSlit2 D2 mutants were puri-
fied to homogeneity from the condi-
tioned medium of episomally trans-
fected 293 cells (data not shown).
Heparin affinity chromatography
unexpectedly revealed that hSlit2
D2 has considerably higher affinity
for heparin than its Drosophila
orthologue (0.85 M NaCl required
for elution, compared with 0.28 M
for Drosophila Slit D2); the biologi-
cal relevance of this difference (if
any) remains to be established.
Mutation of basic residues in the
N-terminal half of hSlit2 D2
(mutants 1–4) had no effect on hep-
arin binding, whereas mutation of
basic residues in the C-terminal
region (mutants 5–7 and the quad-
ruple mutant 5  6) resulted in a
substantial decrease of heparin
affinity (Table 1). Crucially, when
we examined the biological activity
of two mutants that showed the
most reduced heparin binding
(mutants 7 and 5 6), we found that
both mutants had lost the ability to
trigger growth cone collapse (Table
1). These results demonstrate that
the C-terminal cap region of Slit D2 harbors a functionally crit-
ical binding site for heparin/HS.
DISCUSSION
Several growth factors and cytokines require heparin/HS for
productive signaling. The classic example is fibroblast growth
factor (FGF), which requires HS as an obligatory co-receptor
for signaling (25, 26). HS also binds to the FGF receptor (FGFR)
(27), and specific HS sequences support signaling (16). Recent
crystallographic studies have confirmed that a ternary complex
is formed by these partners (28, 29). Although the structural
details of the ternary signaling complex are still a matter of
dispute, it is clear that an important role of heparin/HS is to
stabilize the relatively weak binary interaction between FGF
and FGFR.
In previous studies, HS was shown to be required for Slit-
Robo signaling in vitro (9) and in vivo (10–13, 22–24), but the
molecular mechanism(s) involved remained unclear. Our pre-
vious results have shown that Robo binds to a highly conserved
site on the concave face of Slit D2 (5). In this study, we show that
FIGURE 5. Location of conserved basic residues in hSlit2 D2. A, alignment of D2 domain sequences from
Caenorhabditis elegans, Drosophila melanogaster, and Xenopus laevis Slit and human Slit1–3. Conserved resi-
dues are in boldface; cysteines are red; residues involved in Robo binding (5) are shaded black, and basic
residues mutated in this study (see Table 1) are shaded yellow. The domain structure is indicated above the
alignment (NCAP andCCAP, cap domains; LRR1–6, leucine-rich repeats 1–6). The hSlit2 sequence numbering is
given below the alignment. B, electrostatic surface representation of a molecular model of hSlit2 D2. Positive
andnegativepotential is indicatedbyblueand red coloring, respectively. Theviewdirection is onto theconcave
face of the D2 domain, with the N- and C-terminal caps at the left and right, respectively. The location of
residues involved in Robobinding (Tyr356, Leu378, Tyr404, andHis426) andof basic residuesmutated in this study
are labeled.
TABLE 1
Heparin binding and growth cone collapse activity of hSlit2 D2
mutants
Heparin binding is expressed as the molar NaCl concentration required for elution
from a heparin HiTrap column. The growth cone collapse assay was performed and
quantified as in Fig. 4 (ND indicates not determined).
Mutations Heparinbinding
Percent growth cone
collapse S.E.
TBS 26.7 1.5
Wild type 0.85 60.2 3.1
Mutant 1 R287A 0.84 ND
Mutant 2 R306A 0.86 ND
Mutant 3 K324A/K325A 0.83 ND
Mutant 4 R327A/R328A 0.85 ND
Mutant 5 R461A/R462A 0.64 ND
Mutant 6 K466A/R467A 0.69 ND
Mutant 7 K472A/K475A 0.58 26.8 5.4
Mutant 5 6 R461A/R462A/K466A/R467A 0.48 35.0 3.5
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heparin/HS binding to a conserved basic patch adjacent to the
Robo-binding site is critical for the biological activity of Slit D2.
Furthermore, we provide direct biochemical evidence for a ter-
nary complex consisting of Slit D2, Robo, and heparin.We con-
clude that heparin/HS is an integral and essential component of
the Slit-Robo signaling complex.
Slit concentrations in vivo are likely to be much lower than
the Slit D2 concentration required for growth cone collapse in
vitro, and one function of the high affinity heparin-binding site
in the C-terminal region of Slit may be to concentrate the Slit
protein at the target cell surface or modulate its diffusion
through extracellular matrix (12). This interpretation could
explain why excess heparin/HS abolishes growth cone collapse
triggered by full-length Slit (8, 9) but not by the isolated D2
domain (Fig. 4). We think that exogenous heparin/HS com-
petes with cell surface HS for binding to the CT domain of the
full-length protein, thereby preventing Slit recruitment to the
growth cone surface. The D2 domain, in contrast, is present at
40 nM in our assay, and HS is no longer required for cell surface
localization. Thus, we speculate that HSmay play a dual role in
Slit-Robo signaling, by acting both as a modulator of Slit distri-
bution (12) and as an essential component of the signaling com-
plex (this study). Slits are naturally processed by proteolytic
cleavage within the EG5-EG6 linker (1). The functional rele-
vance of Slit processing is currently not understood, but it is
intriguing that cleavage results in the separation of the two
heparin/HS-binding regions of Slit.
A number of previous studies in vivo have provided evidence
to suggest that specific HS structures are involved in retinal
axon guidance and Slit-Robo signaling (22–24, 30). Because Slit
contains multiple heparin/HS-binding sites (Fig. 1), it is diffi-
cult to assess whether the observed effects are due to an effect
on Slit distribution (HS binding to the CT domain) or signaling
(HS binding to the D2 domain), or both. By applying recombi-
nant D2 domain (mutants) and exogenous heparin derivatives
to growth cones lacking cell surface HS, we should be able to
define precisely the HS sequence(s) required for Robo activa-
tion. In this regard, it is interesting to compare the impact of Slit
D2 mutations on heparin binding and biological activity. Even
though we failed to disrupt heparin binding completely, we
were able to abrogate all activity in the growth cone collapse
assay. Evidently, the requirements for Slit D2 binding to cell
surface HS are more stringent than for binding to
heparin-Sepharose.
In conclusion, our results have revealed a specific role for
heparin/HS in forming a ternary signaling complex with Slit D2
and Robo. At first glance, the parallels to the FGF-FGFR system
are striking, but there are important differences that make it
unlikely that the analogy extends to the mechanism of trans-
membrane signaling. First, Slits are large extracellular matrix
proteins, whereas FGFs are small single-domain proteins. Sec-
ond, Robos are cell adhesionmolecules with no recognized cat-
alytic activity in their cytosolic domains (7, 31), whereas FGFRs
contain cytosolic tyrosine kinase domains. In the FGF-FGFR
system, heparin/HS collaborates with FGF to promote receptor
dimerization, which is required for FGFR autophosphorylation
and downstream signaling (28, 29). In the Slit-Robo system, the
oligomerization state of Robo and the mechanism of trans-
membrane signaling remain to be established. Conceivably,
multiple Slit-Robo signaling complexes could be assembled
upon a single HS chain, but Slit and HS could also disrupt an
inactive Robo oligomer to initiate signaling.
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